IGM Biosciences price target lowered to $1 from $2 at Truist

Truist lowered the firm’s price target on IGM Biosciences (IGMS) to $1 from $2 and keeps a Hold rating on the shares. The firm has updated tis model to reflect Q1 financial results and the company’s forward outlook, adding that it is waiting for any potential announcement regarding a strategic pivot from the company, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on IGMS:

Disclaimer & DisclosureReport an Issue